Drug interactions
Lorlatinib + Polatuzumab vedotin
Severity: Minor
Lorlatinib and Polatuzumab vedotin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Polatuzumab releases MMAE, which is a CYP3A4 substrate. Lorlatinib may lower unconjugated MMAE exposure, with uncertain effect on efficacy.
What this interaction means in plain words
Lorlatinib and Polatuzumab vedotin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Lorlatinib belongs to Oncology; Polatuzumab vedotin belongs to Oncology.
Why it happens
Lorlatinib induces CYP3A4, increasing clearance of free MMAE.
What to do
No dose change is required. Monitor lymphoma response.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lorlatinib and Polatuzumab vedotin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Other interactions of Polatuzumab vedotin
Frequently asked questions
Can I take Lorlatinib with Polatuzumab vedotin?
MediHelp rates the interaction as minor. Lorlatinib and Polatuzumab vedotin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Polatuzumab releases MMAE, which is a CYP3A4 substrate. Lorlatinib may lower unconjugated MMAE exposure, with uncertain effect on efficacy.
How serious is the interaction between Lorlatinib and Polatuzumab vedotin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose change is required. Monitor lymphoma response.
What other medicines interact with Lorlatinib?
MediHelp also lists interactions of Lorlatinib with, for example, Amobarbital, Apalutamide, Butabarbital. The full list is on the Lorlatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
